Both domestic and foreign guidelines to treat hormone receptor-positive breast cancer recommend a CDK4/6 inhibitor combined with endocrine therapy as the preferred initial treatment for patients with luminal-type breast cancer following the development of endocrine therapy. The gene discussed is CDK4; the disease is breast carcinoma.